No patients have received Casgevy, CRISPR Therapeutics and Vertex Pharmeceuticals’ recently approved sickle cell gene therapy ...

Kendric Cromer, 12, is among the first patients to be treated with gene therapy just approved by the F.D.A. that many other ...

Developed in collaboration with Vertex Pharmaceuticals, this therapy treats sickle cell ... editing the faulty gene in a lab, ...

In the meantime current gene therapies remain expensive and challenging to scale up because each patient’s batch of cells has ...

which was later acquired by Vertex Pharmaceuticals for $950 million. Semma was named after Melton’s now grown-up children, aimed at moving a laboratory breakthrough into the real world.

A pharmaceutical company has hosted more than 60 paid interns since opening its purpose-built lab in 2021, in an attempt to ...

Sickle cell disease causes severe pain that’s hard to treat, but researchers are finding new ways to offer relief ...

Stocks in this week’s article are HCA Healthcare HCA, Hubbell HUBB, Ferrari RACE and Vertex VERX. 4 GARP Stocks to ...

Vertex Pharmaceuticals ... Being an ex vivo cell therapy in which patient's cells are harvested, engineered in a lab, and the reinfused back into the patient, the entire treatment process can ...

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. HCA, HUBB, RACE and VERX are some stocks that hold promise.

Israeli data protection company Own became the subject of one the biggest exits in Israel’s technology industry in the past ...